Kwang Dong Sitagliptin Phosphate Hydrate Tablet 100 mg
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Kwang Dong Pharmaceutical Co., Ltd.
MFDS item code 201502369 · Approved 2015.04.17
This product's status changed to Expired on 2025.04.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to assist in blood sugar control for patients with type 2 diabetes. It can initially be administered alone, and if patients without prior experience of diabetes medication find it difficult to manage blood sugar with monotherapy, it may be combined with metformin. Additionally, when sufficient blood sugar control is not achieved with sulfonylureas, metformin, thiazolidinediones, or insulin monotherapy, this medication can be administered in combination. If blood sugar control remains difficult after combination therapy with sulfonylureas and metformin, thiazolidinediones and metformin, or insulin and metformin, this medication may be added to enhance blood sugar control.
When used as monotherapy or in combination therapy, this drug is administered at a dose of 100 mg once daily; the maximum daily dose is 100 mg. This drug may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered without regard to the timing of dialysis.
This medication may cause serious allergic reactions in some patients. These reactions may occur within three months of initial administration, so caution is required. There is a risk of acute pancreatitis, which is inflammation of the pancreas, during the use of this medication; therefore, if symptoms of pancreatitis such as abdominal pain, nausea, or vomiting occur, consult a physician immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in patients who have an allergy to this medication or its ingredients. Patients with decreased renal function should have their dosage adjusted; therefore, appropriate dosages should be determined through renal function tests. During the use of this medication, cold-like symptoms, headaches, gastrointestinal symptoms (abdominal pain, nausea, diarrhea) may occur, and some patients may experience hypoglycemia. Particularly when combined with insulin or sulfonylureas, there may be an increased risk of hypoglycemia, and dosage adjustment may be necessary. Rare adverse effects such as severe joint pain or skin blistering have been reported among patients taking this medication; if any of these symptoms appear, notify a doctor immediately and discontinue the medication. Use of this medication is not recommended for pregnant or breastfeeding women, and its safety and efficacy in children and adolescents under 18 years have not been confirmed. Elderly patients may experience decreased renal function, so renal function should be assessed before taking this medication, along with careful monitoring. In the case of overdose, general treatment should be administered, and blood dialysis may be considered as needed. This medication has relatively low drug interaction with other diabetes treatments, but caution is necessary when taken with specific medications.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air from entering, and it is best kept at room temperature between 1°C and 30°C. Proper storage will maintain the medication's effectiveness and prevent degradation.
Beige, round, biconvex film-coated tablet
In-house packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Kwang Dong Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.